| Hospice Of Central Arkansas 1403 Central Avenue, Hot Springs, AR, 71901 | |
| (501) 623-2076 |
News Archive
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Adult men born with a severe urological anomaly in which the bladder forms outside of the abdomen report much more robust sexual lives than women born with the same condition, according to a small study led by urologists at the Johns Hopkins Children's Center.
› Verified 5 days ago
| Name | Hospice Of Central Arkansas |
|---|---|
| Location | 1403 Central Avenue, Hot Springs, Arkansas |
| Hospice ID | 041511 |
| Category | Freestanding Hospice |
| Ownership Type | Other |
| Profit Type | OTHER |
| SSA county code | 250 |
News Archive
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Adult men born with a severe urological anomaly in which the bladder forms outside of the abdomen report much more robust sexual lives than women born with the same condition, according to a small study led by urologists at the Johns Hopkins Children's Center.
› Verified 5 days ago
| NPI Number | 1124268719 |
| Organization Name | Hospice Of Central Arkansas, Llc |
| Address | 835 Central Ave Hot Springs, Arkansas, 71901 |
| Phone Number | (501)623-2076 |
News Archive
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Adult men born with a severe urological anomaly in which the bladder forms outside of the abdomen report much more robust sexual lives than women born with the same condition, according to a small study led by urologists at the Johns Hopkins Children's Center.
› Verified 5 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.2 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 98.5 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 96.8 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Adult men born with a severe urological anomaly in which the bladder forms outside of the abdomen report much more robust sexual lives than women born with the same condition, according to a small study led by urologists at the Johns Hopkins Children's Center.
› Verified 5 days ago
| Home Health Aides | 8.8 |
| Counselors | 1 |
| Licensed Practical or Vocational Nurses | 2.4 |
| Medical Social Workers | 1.8 |
| Registered Nurses | 10.2 |
| Other Personnel | 7.4 |
| Total Employees | 31.6 |
|---|
News Archive
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Adult men born with a severe urological anomaly in which the bladder forms outside of the abdomen report much more robust sexual lives than women born with the same condition, according to a small study led by urologists at the Johns Hopkins Children's Center.
› Verified 5 days ago
| Others | 5 |
| Total Volunteers | 5 |
|---|
News Archive
RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
A report in Cancer Research, a journal of the American Association for Cancer Research, highlights a new biomarker that may be useful in identifying patients with recurrent glioblastoma, or brain tumors, who would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib.
Adult men born with a severe urological anomaly in which the bladder forms outside of the abdomen report much more robust sexual lives than women born with the same condition, according to a small study led by urologists at the Johns Hopkins Children's Center.
› Verified 5 days ago
| Hospice Of Central Arkansas Location: 1403 Central Avenue, Hot Springs, Arkansas, 71901 Phone: (501) 623-2076 |
| Kindred Hospice I Location: 2212 Malvern Avenue,, Hot Springs, Arkansas, 71901 Phone: (501) 623-2076 |